Report Spotlights Progress, Challenges in Oncology Practice
Applied Clinical Trials
New ASCO study evaluating the cancer care system reveals mixed findings.
A new study by the American Society of Clinical Oncology (ASCO) chronicles the current realities of the cancer care system and examines trends in the oncology workforce and practice environment that are affecting patient care and access. The report is titled "The State of Cancer Care in America: 2015."
According to the ASCO report, there is a wider array of treatment options than ever before for many cancers. In 2014, the FDA added 10 new treatments to its list of more than 170 approved anti-cancer agents, and also approved four new medical devices and tests that may improve patient outcomes through early detection of cancer. In addition, more than 770 cancer therapies are in the research and development pipeline and therapies are demonstrating dramatic improvements in efficacy.
However, the report noted growing challenges to high-quality care delivery, some are as follows:
- Due largely to an aging population, a dramatic 45% increase in cancer incidence is expected by 2030, leading to an overwhelming demand for cancer care and post-treatment services in the relatively near future.
- Benefits of cancer screening and treatment advances have not been experienced consistently across racial and ethnic groups, as evidenced by differences in incidence and mortality rates. African Americans, for example, are 2.5% more likely to develop cancer than whites and 19.6% more likely to die from cancer.
- Nation's ability to care for an increasing number of people with cancer depends on a workforce that is sufficient in size, diversity, and geographic reach.
- Continuation of practice consolidations, as one quarter of all community-based oncology practices report the likelihood of becoming affiliated with a hospital over the next year.
- Industry needs to find better ways to pay for and incentivize high-quality, value-based care. ASCO is currently developing and testing an alternative payment approach that reflects the current realities of oncology practices and ensures that patients receive the full range of services that are integral to their care.
ASCO made several recommendations directed to Congress, one of which calls on increasing the budgets of the National Institutes of Health and the National Cancer Institute by at least $32 billion and $5.32 billion, respectively. View the full release here: http://bit.ly/1y2htXm.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
